ArticleNeuroImage. Clinical2022
Multiple sclerosis lesions and atrophy in the spinal cord: Distribution across vertebral levels and correlation with disability.
Article in NeuroImage. Clinical, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 30 citations in OpenAlex.
- Spinal cord imaging in multiple sclerosis: A vital component we can no longer overlook.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Pooled it
- Spinal cord imaging in multiple sclerosis: from diagnosis to disease progression.Journal of neurology · 2026Review
- Combined clemastine fumarate and selenomethionine promote remyelination via PI3K/Akt/mTOR signaling in experimental multiple sclerosis.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Upper Cervical Cord Area as a Biomarker of Conversion to Secondary Progressive Multiple Sclerosis.Annals of clinical and translational neurology · 2026Article
- Association Between Motor Pathway Damage and Motor Deficit in Upper and Lower Limb in People With MS.Annals of clinical and translational neurology · 2026Article
- Generalizable spinal cord multiple sclerosis lesion segmentation across MRI contrasts, protocols, and centers.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Cervical cord atrophy correlates with intracranial lesion burden in tumefactive multiple sclerosis.Journal of neurology · 2025Article
- AI-driven reclassification of multiple sclerosis progression.Nature medicine · 2025Article
- Spatiotemporal subtypes of brain and spinal cord atrophy in neuromyelitis optica spectrum disorders and multiple sclerosis.BMC medicine · 2025Article
- Cervical spinal cord gray matter damage predicts disability worsening in multiple sclerosis: a longitudinal study.Journal of neurology · 2025Article
- Optimization of cervical cord atrophy measurement using a real-world, multicentre dataset in multiple sclerosis.Frontiers in neurology · 2025Article
- Automatic segmentation of spinal cord lesions in MS: A robust tool for axial T2-weighted MRI scans.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Leveling up: along-level diffusion tensor imaging in the spinal cord of multiple sclerosis patients.Frontiers in neuroimaging · 2025Article
- Tract-specific analysis of diffusion MRI at 3T detects cervical spinal cord aberrations in multiple sclerosis.Imaging neuroscience (Cambridge, Mass.) · 2025Article
- Cervical spinal cord morphometrics in degenerative cervical myelopathy: quantification using semi-automated normalized technique and correlation with neurological dysfunctions.The spine journal : official journal of the North American Spine Society · 2024Article
- Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.Journal of neurology · 2024Review
- MR Imaging Features of Critical Spinal Demyelinating Lesions Associated with Progressive Motor Impairment.AJNR. American journal of neuroradiology · 2024Observational
- Immune-Mediated Myelopathies.Continuum (Minneapolis, Minn.) · 2024Article
- Spinal cord evaluation in multiple sclerosis: clinical and radiological associations, present and future.Brain communications · 2024Review
- Prognostic value of spinal cord lesion measures in early relapsing-remitting multiple sclerosis.Journal of neurology, neurosurgery, and psychiatry · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundThe vast majority of magnetic resonance imaging (MRI) studies on multiple sclerosis (MS) covered the spinal cord (SC), if at all, incompletely.
objectiveTo assess SC involvement in MS, as detectable by whole SC MRI, with regard to distribution across vertebral levels and relation to clinical phenotypes and disability.
methodsWe investigated SC MRI with sagittal and axial coverage. Analyzed were brain and SC MRI scans of 17 healthy controls (HC) and of 370 patients with either clinically isolated syndrome (CIS, 27), relapsing remitting MS (RRMS, 303) or progressive MS (PMS, 40). Across vertebral levels, cross-sectional areas were semiautomatically segmented, and lesions manually delineated.
resultsThe frequency of SC lesions was highest at the level C3-4. The volume of SC lesions increased from CIS to RRMS, and from RRMS to PMS whereas lesion distribution across SC levels did not differ. SC atrophy was demonstrated in RRMS and, to a higher degree, in PMS; apart from an accentuation at the level C3-4, it was evenly distributed across SC levels. SC lesions and atrophy volume were not correlated with each other and were independently associated with disability.
conclusionSC lesions and atrophy already exist at the stage of RRMS in the whole SC with an accentuation in the cervical enlargement; SC lesions and atrophy are more pronounced in the stage of PMS. Both contribute to the clinical picture but are largely independent.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.